AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical trials for AMYOTROPHIC LATERAL SCLEROSIS (ALS) explained in plain language.
Never miss a new study
Get alerted when new AMYOTROPHIC LATERAL SCLEROSIS (ALS) trials appear
Sign up with your email to follow new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested to slow ALS progression
Disease control CompletedThis study tested whether a drug called MCI-186 could help control the progression of ALS (Lou Gehrig's disease). It involved 25 people with moderate ALS who received either the drug or a placebo through daily IV infusions for 24 weeks. Researchers measured changes in physical fu…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Major ALS drug trial tests potential to slow disease progression
Disease control CompletedThis Phase 3 study tested whether the drug MCI-186 could help control ALS symptoms and slow disease progression. 206 people with ALS received either the drug or a placebo through daily IV drips for 24 weeks. Researchers measured changes in physical function, breathing ability, an…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Scientists test Long-Term ALS drug to slow devastating decline
Disease control CompletedThis study tested whether long-term, repeated treatment with the drug edaravone (MCI-186) could help control the progression of ALS, a severe nerve disease. It involved 181 patients who had already completed a prior 24-week trial. Researchers measured changes in patients' ability…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Race against time: drug trial aims to slow devastating ALS progression
Disease control CompletedThis study tested whether a drug called MCI-186 (now known as edaravone) could slow the worsening of ALS symptoms. It involved 137 people with early-stage ALS who could still manage daily activities independently. For 24 weeks, participants received either the drug or a placebo t…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Blood test matches ALS patients to supplements in quest to slow disease
Disease control CompletedThis pilot study tested a personalized approach for ALS (Lou Gehrig's disease). Researchers used a blood analysis platform to categorize 50 participants into one of four biological problem areas linked to ALS. Based on their category, participants received a specific dietary supp…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Mar 23, 2026 15:28 UTC
-
Two-Year safety check for promising ALS pill
Disease control CompletedThis study aimed to check the long-term safety of an oral medication called edaravone for people with ALS over two years. It was an extension study for 124 participants who had already completed a previous trial. The main goal was to monitor for any side effects or health problem…
Matched conditions: AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC